[HTML][HTML] Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
KH Bjørlykke, HS Ørbo, AT Tveter, I Jyssum… - The Lancet …, 2023 - thelancet.com
Background Data on response and safety of repeated vaccinations and hybrid immunity in
patients with immune-mediated inflammatory diseases on immunosuppressive therapy is …
patients with immune-mediated inflammatory diseases on immunosuppressive therapy is …
[PDF][PDF] Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
KH Bjørlykke, HS Ørbo, AT Tveter, I Jyssum, J Sexton… - 2022 - colmedicosantafe2.org.ar
Background Data on response and safety of repeated vaccinations and hybrid immunity in
patients with immunemediated inflammatory diseases on immunosuppressive therapy is …
patients with immunemediated inflammatory diseases on immunosuppressive therapy is …
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study.
KH Bjørlykke, HS Ørbo, AT Tveter, I Jyssum… - The Lancet …, 2022 - europepmc.org
Background Data on response and safety of repeated vaccinations and hybrid immunity in
patients with immune-mediated inflammatory diseases on immunosuppressive therapy is …
patients with immune-mediated inflammatory diseases on immunosuppressive therapy is …
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
KH Bjørlykke, HS Ørbo, AT Tveter, I Jyssum… - The Lancet …, 2023 - Elsevier
Background Data on response and safety of repeated vaccinations and hybrid immunity in
patients with immune-mediated inflammatory diseases on immunosuppressive therapy is …
patients with immune-mediated inflammatory diseases on immunosuppressive therapy is …
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
KH Bjørlykke, HS Ørbo, AT Tveter… - The Lancet …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Data on response and safety of repeated vaccinations and hybrid immunity in
patients with immune-mediated inflammatory diseases on immunosuppressive therapy is …
patients with immune-mediated inflammatory diseases on immunosuppressive therapy is …
[HTML][HTML] Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
KH Bjørlykke, HS Ørbo, AT Tveter, I Jyssum… - The Lancet …, 2023 - ncbi.nlm.nih.gov
Background Data on response and safety of repeated vaccinations and hybrid immunity in
patients with immune-mediated inflammatory diseases on immunosuppressive therapy is …
patients with immune-mediated inflammatory diseases on immunosuppressive therapy is …
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study.
KH Bjørlykke, HS Ørbo, AT Tveter, I Jyssum… - The Lancet …, 2022 - europepmc.org
Background Data on response and safety of repeated vaccinations and hybrid immunity in
patients with immune-mediated inflammatory diseases on immunosuppressive therapy is …
patients with immune-mediated inflammatory diseases on immunosuppressive therapy is …